Cue Historical Cash Flow
| CUE Stock | USD 1.01 0.01 0.98% |
Analysis of Cue Biopharma cash flow over time is an excellent tool to project Cue Biopharma future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 449.4 K or Depreciation of 3.6 M as it is a great indicator of Cue Biopharma ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cue Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cue Biopharma is a good buy for the upcoming year.
Cue |
About Cue Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cue balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cue's non-liquid assets can be easily converted into cash.
Cue Biopharma Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Cue Biopharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 94.5 K, whereas Change In Cash is projected to grow to (2.9 M).
| 2010 | 2023 | 2024 (projected) | Dividends Paid | 199.9K | 179.9K | 159.9K | Net Borrowings | 10M | 16.7M | 12.3M |
Cue Biopharma cash flow statement Correlations
Click cells to compare fundamentals
Cue Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cue Biopharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (91.0K) | (271.1K) | (750.2K) | (200K) | (230K) | (241.5K) | |
| Investments | (15.1M) | (9.9M) | 10M | (29.4M) | 25.0M | 26.3M | |
| Change In Cash | 23.4M | 30.6M | (10.5M) | (12.8M) | (3.1M) | (2.9M) | |
| Free Cash Flow | (30.8M) | (33.1M) | (39.8M) | (42.0M) | (40.0M) | (42.0M) | |
| Change In Working Capital | (1.5M) | 1.2M | (4.4M) | 356.3K | (934K) | (887.3K) | |
| Total Cashflows From Investing Activities | 3.4M | 4.5M | 9.1M | (24.6M) | (22.1M) | (21.0M) | |
| Other Cashflows From Financing Activities | 1.9M | 1.9M | 1.8M | 4.4M | 473K | 449.4K | |
| Depreciation | 5.2M | 1.1M | (1.8M) | 1.8M | 3.4M | 3.6M | |
| Other Non Cash Items | (4.3M) | (563.2K) | (26.1K) | (453.8K) | 90K | 94.5K | |
| Capital Expenditures | 1.9M | 46.4K | 595.3K | 913.0K | 170.7K | 0.0 | |
| Total Cash From Operating Activities | (30.8M) | (32.5M) | (38.8M) | (41.8M) | (40.0M) | (42.0M) | |
| Change To Operating Activities | (3.9M) | 1.2M | (3.2M) | (2.2M) | (2.0M) | (1.9M) | |
| Net Income | (36.7M) | (44.8M) | (44.2M) | (53.0M) | (50.7M) | (53.3M) | |
| Total Cash From Financing Activities | 50.8M | 58.6M | 19.2M | 53.7M | 11.9M | 11.3M | |
| End Period Cash Flow | 44.4M | 75.0M | 64.5M | 51.8M | 48.7M | 47.7M | |
| Other Cashflows From Investing Activities | 18.6M | (83.7K) | 21.6K | (24.4M) | 2K | 1.9K | |
| Change To Netincome | 6.6M | 9.9M | 11.5M | 9.5M | 10.9M | 7.4M | |
| Change To Liabilities | (713.4K) | 1.3M | 2.4M | (987.5K) | (1.1M) | (1.1M) | |
| Stock Based Compensation | 6.5M | 10.5M | 11.5M | 9.5M | 8.2M | 7.8M | |
| Begin Period Cash Flow | 21.0M | 44.4M | 75.0M | 64.5M | 51.8M | 47.0M | |
| Cash And Cash Equivalents Changes | 23.4M | 30.6M | (10.5M) | (12.8M) | (14.7M) | (13.9M) | |
| Cash Flows Other Operating | (15.7K) | 593.6K | (2.0M) | (1.0M) | (923.1K) | (876.9K) | |
| Issuance Of Capital Stock | 49.0M | 56.7M | 17.4M | 39.3M | 13.4M | 24.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.